Analyst: New Genmab approval shows portfolio potential

The approval of the drug Tivdak, which is developed by Genmab and its partner Seagen, is in many ways a milestone achievement for the Danish biotech company, explains Senior Analyst at Sydbank Søren Løntoft Hansen.

Photo: Tuala Hjarnø / Genmab / PR

This isn't the first approval of a Genmab-developed drug, nor is it the first cancer drug that the Danish biotech company is behind. Nonetheless, the approval of tisotumab vedotin, under the commercial name Tivdak, by the US Food and Drug Administration (FDA) is an important stepping stone on the path forward, says Søren Løntoft Hansen, senior analyst at Sydbank.

"The approval of Tivdak is very positive in the way it contributes to the gradually growing portfolio of approved medicines coming from Genmab laboratories, which emphasizes that Genmab is now more than just Darzalex," he tells MedWatch.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs